Horizon lowers expectations for Tepezza and adjusts its strategy for the year ahead

Tyler Patchen

News Reporter

One of Horizon Therapeutics’ top sellers isn’t performing as well as expected, CEO Tim Walbert revealed on Wednesday’s Q2 call, leading the pharma company to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Horizon lowers expectations for Tepezza and adjusts its strategy for the year ahead

Tyler Patchen

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Hori­zon low­ers ex­pec­ta­tions for Te­pez­za and ad­justs its strat­e­gy for the year ahead

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Horizon lowers expectations for Tepezza and adjusts its strategy for the year ahead